Want to see JP:4891 full AI Analyst Report?
4891 Stock Chart & Stats
¥129.00
-¥1.00(-0.47%)
At close: 4:00 PM EST
¥129.00
-¥1.00(-0.47%)
Day’s Range― - ―
52-Week Range¥92.00 - ¥165.00
Previous CloseN/A
Volume100.70K
Average Volume (3M)338.08K
Market Cap
¥6.88B
Enterprise Value¥2.51B
Total Cash (Recent Filing)¥3.18B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.99
Shares Outstanding48,458,466
10 Day Avg. Volume398,140
30 Day Avg. Volume338,076
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-25.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA debt-free balance sheet reduces mandatory interest and repayment demands, giving TMS greater resilience during operating losses. This conservative financing profile preserves financial flexibility and may allow management to direct available resources toward research, development, or recovery initiatives.
Demonstrated Historical ProfitabilityThe 2022 result shows that TMS has previously generated meaningful revenue and positive earnings, indicating the business has at least demonstrated commercial potential. Re-establishing comparable operating performance could provide a foundation for improved earnings stability over the medium term.
Prior Cash GenerationStrong positive cash flow in 2022 provides evidence that the company has previously converted operations into cash rather than relying continuously on external funding. Although later periods weakened, this historical capacity is a constructive reference point for a potential operational recovery.
Bears Say
Persistent Operating LossesSeveral consecutive years of deep operating and net losses indicate that current activities are not producing dependable earnings. This weak profitability can consume capital, restrict reinvestment, and make a sustained recovery dependent on improved commercialization or additional funding.
Recurring Cash BurnRepeated negative operating and free cash flow shows that the business is consuming cash through its ongoing activities. Persistent burn reduces financial flexibility, increases the importance of funding access, and can pressure the company to limit investment or raise capital before profitability returns.
Shrinking Equity BaseDeclining equity alongside mostly negative returns on equity suggests that continuing losses are eroding the company’s capital base. Even without reported debt, further deterioration could reduce the cushion available to support research, absorb setbacks, or finance operations internally.
TMS Co., Ltd. News
4891 FAQ
What was TMS Co., Ltd.’s price range in the past 12 months?
TMS Co., Ltd. lowest stock price was ¥92.00 and its highest was ¥165.00 in the past 12 months.
What is TMS Co., Ltd.’s market cap?
TMS Co., Ltd.’s market cap is ¥6.88B.
When is TMS Co., Ltd.’s upcoming earnings report date?
TMS Co., Ltd.’s upcoming earnings report date is Nov 13, 2026 which is in 14 days.
How were TMS Co., Ltd.’s earnings last quarter?
TMS Co., Ltd. released its earnings results on Aug 14, 2026. The company reported -¥4.15 earnings per share for the quarter.
Is TMS Co., Ltd. overvalued?
According to Wall Street analysts TMS Co., Ltd.’s price is currently Overvalued.
Does TMS Co., Ltd. pay dividends?
TMS Co., Ltd. does not currently pay dividends.
What is TMS Co., Ltd.’s EPS estimate?
TMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TMS Co., Ltd. have?
TMS Co., Ltd. has 48,458,466 shares outstanding.
What happened to TMS Co., Ltd.’s price movement after its last earnings report?
TMS Co., Ltd. reported an EPS of -¥4.15 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of TMS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4891
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TMS Co., Ltd.
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.